|
15 Mar 2018
|
Bliss GVS Pharma
|
Choice India
|
155.52
|
250.00
|
197.30
(-21.18%)
|
|
Buy
|
|
|
The Company has established brand operations in existing markets that provide an ideal platform to extend the Bliss GVS product portfolio and with that, build new revenue streams. On the back of significant expansion across both Pharmaceutical & Healthcare verticals, the Company could be poised for an accelerated growth At CMP of Rs. 184.8 ,Bliss GVS Ltd. is trading at a P/E multiple of 12.8(x) compared to the industry peer of 25.2(x). The company has an upside potential of 25% to 30% in the next 12 to 18 months. We arrive at a target price in range of Rs231 to Rs.240....
|
|
09 Jan 2018
|
Bliss GVS Pharma
|
Joindre Capital Services
|
155.52
|
350.00
|
206.95
(-24.85%)
|
|
Buy
|
|
|
Bliss GVS Pharma Ltd. is an Indian pharmaceutical company headquartered in Mumbai, India. Bgvsl primarily develops, manufactures and markets products across various therapeutic categories including Anti-fungal, Contraceptive, Laxative, Anti-haemorrhoidal, Anti-spasmodic, Anti-malarial, Anti-biotic, Anti-microbial, Anti-inflammatory, Antipyretic, Analgesic and several others.BGVSLis among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. It has three decades of experience in suppositories and pessaries. BGVSL most unique product is Today Vaginal Contraceptive', a safe female contraceptive. It is the only EU-GMP certified suppositories and pessaries manufacturer in India. & its portfolio...
|